kelch repeat and BTB domain containing 6Genealiases: []
Q-omics provides the consensus-scored KBTBD6 profile across patient tissues and cancer cell-line models. KBTBD6 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, KBTBD6 is differentially expressed in 16, with the highest sampling consensus in HNSC. Additionally, KBTBD6 RNA expression shows 20,558 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, HNSC, and ACC as cancer lineages where KBTBD6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KBTBD6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KBTBD6 survival associations across molecular data types. KBTBD6 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (3) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KBTBD6 RNA expression–survival associations across cancer types. High KBTBD6 expression shows unfavorable associations in HNSC, ACC and UVM, but favorable associations in KIRC, LUSC and LGG. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for KBTBD6 RNA expression.
This table summarizes KBTBD6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 3. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for KBTBD6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KBTBD6 shows lower tumor expression in KICH and THCA and higher tumor expression in HNSC, COAD, STAD and LIHC. The HNSC box plot shows higher KBTBD6 RNA expression in tumor versus normal tissue (log2 FC = +1.755, t-test p < 0.001).
This table shows molecular features associated with KBTBD6 in patient tissues and cancer cell lines. In patient samples, KBTBD6 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, KBTBD6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in SKIN and UPPER_AERODIGESTIVE_TRACT.
